Schizophrenia: Genome, Interrupted  by Cantor, Rita M. & Geschwind, Daniel H.
to social rewards at the single-neuron
level remains to be seen.
One immediate implication of these
results is for patients with dysfunction of
thesebrain regions. The striatum is among
the targets of some neurological dis-
orders, such as Parkinson’s disease
(PD). Overtreatment of PD with dopamine
agonists is known to induce abnormal
economic decision-making, including
compulsive gambling (Voon et al., 2006).
If the same brain structures are responsi-
ble for the reward-value of love and repu-
tation, pharmacological manipulation of
the striatum may also have social con-
sequences.
The broader questions raised by the
current results concern the relationship
between two basic domains of human
cognition: the social and the economic.
Beyond the common currency, what dis-
tinguishes the processing of social versus
monetary reward? How and when does
sensitivity to these different domains of
reward emerge, during child development
or in evolution? And finally, what neural
processes are engaged when an individ-
ual must trade off one kind of reward
against the other? Taken together, the
tools of behavioral economics, psychol-
ogy, and neuroscience could provide an
answer to how we decide, in the end,
whether to choose love or money.
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Structural chromosomal variation is increasingly recognized as an important contributor to human diseases,
particularly those of neurodevelopment, such as autism. A current paper makes a significant advance to
schizophrenia genetics by establishing an association with rare copy number variants (CNV), which are
over-represented in neurodevelopmental genes.Geneticists have become increasingly
aware of a large amount of previously
unidentified and unanticipated structural
variationwithin the human genome. These
variations, duplications and deletions of
relatively small genomic segments that
range from 1 kb to several million bases,
are referred to as copy number variants
(CNVs). CNVs, like other genetic variants,
come in many forms: they may be in-
herited or de novo, rare or common. Sim-
ilar to single base pair changes, rare de
novo CNVs are often interpreted in thesame way as Mendelian mutations that
may play a causal role in disease and
have been associated with several neuro-
developmental disorders, including intel-
lectual disability andautism (deVrieset al.,
2005; Jacquemont et al., 2006; Stankie-
wicz and Beaudet, 2007; Sebat et al.,
2007; Szatmari et al., 2007). Some CNVs
arise in chromosomal regions of segmen-
tal duplications that allow for inexact
crossovers when the gametes are being
formed (Mehan et al., 2004; Sharp et al.,
2006). Sporadic cases of single-geneNeuroneurological disorders such as Charcot-
Marie-Tooth neuropathy and Smith-
Magenis syndrome derive from de novo
CNVs generated by this mechanism
(Lupski, 2007). However, most of the rare
de novo CNVs arise in the absence of
such repeat regions, consistent with what
appears to be random DNA breakage.
The role of CNVs in common complex
disorders is an area of intense investiga-
tion. Using the molecular technology
of microarray-based methods designed
for both single-nucleotide polymorphismn 58, April 24, 2008 ª2008 Elsevier Inc. 165
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tion, they are beginning to be cataloged
in psychiatric and neurological disorders
(Sebat et al., 2007; Szatmari et al., 2007;
Marshall et al., 2008). It is on this research
background that Walsh et al. (Walsh et al.,
2008) report an excess of CNVs in patients
with schizophrenia in the journal Science.
Schizophrenia represents a typical com-
plex genetic disorder, with most cases
previously thought to be due to the action
of multiple genes interacting with each
other and the environment. The incidence
of schizophrenia is about 1%, and the
sibling recurrence risk is about 5%–10%,
making the case for its familiality, and twin
studies indicate a high heritability (about
80%) (Sullivan, 2008). Genetic heteroge-
neity and the complexity of the phenotype
have challenged whole genome linkage
studies, which have been inconsistent,
and despite a large number of published
candidate gene studies, only a few genes,
including DISC1 and neuregulin1 are
considered strong candidates (Sullivan,
2008). Particularly relevant to the current
report, DISC1, perhaps the schizophre-
nia-causing gene with the strongest
evidence, was identified by a dominantly
inherited chromosomal abnormality in a
single pedigree. It is therefore anticipated
that the disruption, deletion, and duplica-
tion of whole genes in the individuals re-
ported by Walsh and colleagues (Walsh
et al., 2008) represents a significant
advance in the field.
This manuscript reports a CNV analysis
of two samples: the first with mixed ages
of onset of schizophrenia, and the second
consisting of only subjects with childhood
onset schizophrenia. Thefirst ‘‘test’’ group
included 150 individuals with schizophre-
nia and 268 controls who were ancestry
matched and 35 or older, without signs
of neurological or psychiatric illness. Be-
cause many of the CNVs identified are
rare or are only observed in one subject
or family, investigators are not able to pro-
vide statistical evidence of an association
with a specific CNV. Rather, they investi-
gate whether such CNVs are increased
in aggregate in those with the disease
compared to the controls. Their working
hypothesis is that ‘‘some mutations pre-
disposing to schizophrenia are highly
penetrant, individually rare, and of recent
origin, even specific to single cases or
families (Walsh et al., 2008).’’ To establish166 Neuron 58, April 24, 2008 ª2008 Elsevithis, the rate of rare CNVs considered col-
lectively should be higher in those with the
disorder than in those who show no evi-
dence of it. Similar designs have been ap-
plied in autism spectrum disorders (ASD).
In addition to the increased rate of rare
de novo CNVs in ASD (about 10% in sim-
plex families), recurrent CNVs on chromo-
some 16p and 15q have been identified,
each accounting for about 1% of patients
(Weiss et al., 2008).
The resolution of themolecular platform
they used allows them to detect CNVs of
a size greater than 100 kb, which is about
30 times the resolution of standard cyto-
genetic techniques. Here, common vari-
ants seen at 1% or greater did not differ
in frequency in the cases compared to
controls, so the focus remained on rare
variants. Those variants that delete or
duplicate genes were seen at a rate of
22/150 (or 15%) in cases and 13/268 (or
5%) in controls. The rates for those CNV
disrupting genes were 11% in cases and
4% in controls. Both of these case and
control differences are statistically signifi-
cant, indicating that thosewithschizophre-
nia are more likely to harbor novel CNVs of
a size greater than 100 kb than controls.
Replication of this finding focused on
those with childhood onset schizophrenia
(COS), a relatively rare condition, defined
as those developing schizophrenia before
12 years of age. In the original case/con-
trol sample, there are 76 individuals falling
into an early onset category (onset prior to
age 19), and 20% have a rare deletion.
In the replication sample of 83 COS par-
ent-child trios, 23/76 affected children
aged 12 or less (or 28%) have a rare CNV,
which is higher than the 20% in those with
early onset in the original sample, where
the age cutoff was 18 years. The control
groups between the original and replica-
tion samples are not comparable in that
the one in the replication sample is artifi-
cial and derived from those chromosomes
not transmitted to the schizophrenic
children from their parents, but the associ-
ation of rare CNVs and schizophrenia is
replicated.
Because parental information was not
available in the first sample, but is in the
COS sample (because the parents and
the proband were assayed), it was also
possible to identify those CNVs that are
de novo mutations in the affected child.
So, the investigators used the parent childer Inc.trio data to present the specific CNV in the
affected children classified by whether
they are inherited or de novo (see the Sup-
plemental Tables in Walsh et al., 2008).
The majority are inherited from a parent,
with only two that are de novo, suggesting
that most of the CNVs are not highly pen-
etrant, or the transmitting parent would
exhibit symptoms of schizophrenia. In
addition, several patients have more than
one such CNV, again suggesting that any
predisposing CNV is likely to be interact-
ing with other modifying genetic or envi-
ronmental factors to cause schizophrenia.
Overall, the relative risk of schizophrenia in
those carrying a rare CNV ranges between
3%and 4%, not consistent with aMende-
lian model for the CNVs taken in aggre-
gate. This does not preclude the possibil-
ity of a few individual CNVs operating in
a Mendelian fashion, but such a mecha-
nism has not been proven here. One inter-
esting observation is that those caseswith
early or childhood onset, which can be
considered a more severe form of the dis-
order, had the highest rate of rare CNVs.
Similarly, large de novo CNVs are in-
creased in severe ASD, especially in those
with syndromic forms, relative to the less
severe, familial cases (Jacquemont et al.,
2006; Sebat et al., 2007), which is consis-
tent with the notion that some large de
novo CNVs are highly penetrant, relatively
severe mutations.
The CNVs identified for schizophrenia
in this study are within genic regions rang-
ing from 135 kb to the entire Y chromo-
some (58 Mb) and include from 1 to 20
genes. In controls, CNVs range from197kb
to 3.6 Mb and span the same range for the
number of genes duplicated or deleted.
Because not all genes are dosage sensi-
tive, it is recognized that, within a region
containing many duplicated or deleted
genes, only a subset, or perhaps as few
as one or none, are likely to contribute to
the changes in phenotype observed
in disease. Therefore, the authors focus
most of their analysis on genes actually
disrupted by the CNV breakpoints, be-
cause these genes are most likely to be
functionally deranged. However, it must
also be appreciated that genes within the
CNV in addition to those ruptured by the
chromosomal breakage may also be con-
tributing to disease.
The authors usepathway analysis bioin-
formatics tools to establish that, while the
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those that are seen in schizophrenia are
overrepresented in pathways associated
with brain development. These include
neuregulin signaling, ERK/MAPK sig-
naling, synaptic long-term potentiation,
axonal guidance signaling, integrin signal-
ing, and glutamate receptor signaling,
several of which have been previously
implicated in studies of schizophrenia bi-
ology (Lewis and Gonzalez-Burgos, 2006;
Norton et al., 2006).
Several of the CNVs result in predictable
alterations in gene product function. One
particularly interesting CNV disrupts
ERBB4, a receptor for neuregulin1, which
is one of the few genes having a replicated
common variant associated with schizo-
phrenia (Munafo et al., 2006). Walsh and
colleagues (Walsh et al., 2008) show that
the transcript arising as a consequence of
this medium-sized CNV (400 kb) encodes
an alternate transcript that is predicted to
act in a dominant-negative fashion. But, it
is not described whether this represents
a sporadic or familial case, and thus as-
sessment of the segregation of this variant
with disease is not possible, although it
would clearly alter protein function.
However, several genes important for
neurodevelopment were uniquely disrup-
ted in controls, for example ROBO1 and
SOX5, emphasizing that caution must be
taken when connecting a single rare event
with disease. Thus, among the genes dis-
rupted by CNVs in those with schizophre-
nia are likely to be those that are random,
as seen in controls, and some that are
perhaps specific to schizophrenia. The
authors recognize this in their discussion,
pointing out that these data cannot impli-
cate a role for any specific gene. What is
remarkable, however, is that this single
study provides statistical evidence sup-
porting the involvement of several key
neurodevelopmental pathways in schizo-
phrenia, providing a circumscribed set of
candidate genes within these pathwaysfor further investigation. Their successful
analysis exhibits an important approach
for the study of rare variants in psychiatric
disorders. Inaddition, as sequencing tech-
nologies provide the possibility of deep
resequencing of large numbers of candi-
date genes, a similar approach to identify
rare, single base pair mutations becomes
accessible. The success of Walsh et al.
(2008) in establishing that rare genetic var-
iants are associated with schizophrenia,
in contrast with the ambiguity thus far ob-
served using approaches based on com-
mon variants, suggests that developing
analytic methods focused on identifying
rare mutations is warranted.
The specificity of the identified variants
for schizophrenia remains unknown. For
example, CNVs in Neurexin 1 and recur-
rent CNV on chromosome 16p11 previ-
ously reported in ASD and other neurode-
velopmental disorders were also
observed in this study. This is not prob-
lematic, but rather it presents a significant
opportunity to understand the relation-
ship of these disorders at a molecular
level. If the same genes carry mutations
for the development of schizophrenia or
autism, it suggests genetic pleiotropy,
where multiple disorders derive from mu-
tations in the same gene, and the disorder
is conditional upon the presence of other
modifying alleles, environment factors, or
chance. It also should be recognized that
childhood schizophrenia shares some
clinical features with ASD and has been
considered part of the ASD spectrum in
the past. Thus, fromaneurobiological per-
spective, these genetic data support the
notion of a link between disorders involv-
ing neurodevelopmental processes that
are currently considered to be clinically
distinct. This work makes significant in-
roads in breaking down the somewhat
artificial clinical distinctions between neu-
ropsychiatric diseases and provides sup-
port for defining core phenotypes related
to the common genetic mechanisms.NeuroREFERENCES
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